We are live on ! Find out more
CNMD icon

CONMED

227 hedge funds and large institutions have $2.13B invested in CONMED in 2020 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 78 increasing their positions, 79 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

26% more call options, than puts

Call options by funds: $6.3M | Put options by funds: $4.98M

26% more capital invested

Capital invested by funds: $1.69B → $2.13B (+$440M)

0.03% more ownership

Funds ownership: 103.7%103.73% (+0.03%)

0% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 36

0% less funds holding

Funds holding: 228227 (-1)

1% less repeat investments, than reductions

Existing positions increased: 78 | Existing positions reduced: 79

Holders
227
Holders Change
-1
Holders Change %
-0.44%
% of All Funds
4.64%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
36
Increased
78
Reduced
79
Closed
36
Calls
$6.3M
Puts
$4.98M
Net Calls
+$1.31M
Net Calls Change
+$2.34M

CNMD Hedge Fund Activity: Q2 2020 in Review

227 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in CONMED (CNMD) for Q2 2020, worth a combined $2.13B — up 26% from $1.69B a quarter earlier.

Fund positioning in CNMD was balanced in Q2 2020: 36 funds opened new positions, 36 closed out, 78 added to existing stakes and 79 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $46.3M. The largest seller was Capital Research Global Investors, cutting an estimated $60.2M.

  • 227 institutional investors held CONMED (CNMD) as of Q2 2020, down from 228 in Q1 2020.
  • Funds reported $2.13B of CONMED stock for Q2 2020, up 26% quarter-over-quarter.
  • 36 funds opened new CONMED positions in Q2 2020 and 36 closed out, a net change of 0 holders.
  • The largest CONMED buyer in Q2 2020 was Point72 Asset Management, an estimated $46.3M added.
  • The largest CONMED seller in Q2 2020 was Capital Research Global Investors, an estimated $60.2M sold.

Based on aggregated 13F filings for Q2 2020.